AB53319

FITC Anti-DR5 antibody [DR5-01-1]

Name: Anti-DR5 FITC antibody [DR5-01-1] (ab53319) Mouse monoclonal IgG1 | Abcam
Brand: Abcam Limited
SKU: AB53319
Price: 265 USD
Availability: InStock

Be the first to review this product! Submit a review

(3 Publications)

Mouse Monoclonal DR5 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Recombinant full length protein - Human samples. Cited in 3 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF10B.

View Alternative Names

CD262, DR5, KILLER, TRAILR2, TRICK2, ZTNFR9, UNQ160/PRO186, TNFRSF10B, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2

1 Images

Flow Cytometry - FITC Anti-DR5 antibody [DR5-01-1] (AB53319)

Flow Cyt

Unknown

Flow Cytometry - FITC Anti-DR5 antibody [DR5-01-1] (AB53319)

Flow cytometry analysis (surface staining) of CD262 on CD262-transfectants using ab53319 at 5 μg/ml.

Unconjugated

Anti-DR5 antibody [DR5-01-1]
660 APC

APC Anti-DR5 antibody [DR5-01-1]
578 PE

PE Anti-DR5 antibody [DR5-01-1]

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

DR5-01-1

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human TNFRSF10B. The exact immunogen used to generate this antibody is proprietary information.

O14763

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Recombinant full length protein - Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1-5 µg/mL", "FlowCyt-species-notes": "<p></p>" } } }

style

left-column

Product details

The reagent is free of unconjugated FITC.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein G

Storage buffer

pH: 7.4 Preservative: 0.097% Sodium azide Constituents: PBS, 0.2% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

+4°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

DR5 also known as Death Receptor 5 TRAIL-R2 or TNFRSF10B is a protein critical in apoptosis. It is a transmembrane receptor with a mass of approximately 54 kDa. Researchers find it expressed mostly in tissues such as lung colon and prostate. DR5 functions by binding to its ligand TRAIL triggering the extrinsic apoptotic pathway. Through this mechanism DR5 initiates a cascade of caspase activation that leads to cell death.

Biological function summary

DR5 plays a significant role in the regulation of apoptosis particularly in cancer cells. It is a component of the TRAIL receptor complex which includes several other death receptors like DR4. This complex formation allows DR5 to mediate apoptotic signals more efficiently. By controlling apoptosis DR5 helps maintain tissue homeostasis and prevents abnormal cell proliferation.

Pathways

DR5 is an important part of the TRAIL signaling pathway and the extrinsic apoptosis pathway. It connects with proteins like FADD and Caspase-8 essential in the apoptotic signaling cascade. By interacting with these proteins DR5 drives the progression of the apoptotic signal ensuring the removal of dysfunctional cells. Such pathways are vital for restraining tumor development and progression.

DR5 exhibits significant relevance to cancer and autoimmune diseases. Its ability to induce apoptosis through the TRAIL pathway keeps oncogenic transformations in check. In cancer DR5 often interfaces with other proteins like Bcl-2 which are involved in cell survival. Furthermore defects or aberrant expressions in DR5 have associations with autoimmune disorders where excessive cell death or survival contributes to disease pathology. DR5's role in these conditions makes it a promising target in therapeutic strategies.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed : 10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

See full target information TNFRSF10B

style

left-column

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in cell and developmental biology 12:1478757 PubMed39568509

2024

Deciphering transcriptome patterns in porcine mesenchymal stem cells promoting phenotypic maintenance and differentiation by key driver genes.

Applications

Unspecified application

Species

Unspecified reactive species

Nadia Khaveh,René Buschow,Julia Metzger

Cell 176:1477-1489.e14 PubMed30827683

2019

Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Liqiang Pan,Tian-Min Fu,Wenbin Zhao,Linlin Zhao,Wen Chen,Chixiao Qiu,Wenhui Liu,Zhijun Liu,Alessandro Piai,Qingshan Fu,Shuqing Chen,Hao Wu,James J Chou

Methods in molecular biology (Clifton, N.J.) 1866:61-73 PubMed30725408

2019

Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Strekalova,Dmitry Malin,Harisha Rajanala,Vincent L Cryns

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

FITC Anti-DR5 antibody [DR5-01-1]

Flow Cytometry - FITC Anti-DR5 antibody [DR5-01-1] (AB53319)

Related conjugates and formulations (3)

Key facts

Host species

Clonality

Clone number

Isotype

Conjugation

Excitation/Emission

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (3)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Product promise